Ningling Ge
Impact in
- Hepatology top 1%
- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer Research top 5%
- NF-κB Signaling Pathways
- Cancer, Lipids, and Metabolism
Papers in
- Hepatology 24
- Hepatocellular Carcinoma Treatment and Prognosis 24
- Oncology 22
- Cancer Immunotherapy and Biomarkers 9
- Inflammatory Biomarkers in Disease Prognosis 4
- Pancreatic and Hepatic Oncology Research 4
- Co-authors
- Zhenggang Ren (17 shared papers)Sheng‐Long Ye (12 shared papers)Jia Fan (13 shared papers)Yanhong Wang (11 shared papers)Lan Zhang (14 shared papers)Tong‐Chun Xue (8 shared papers)Boheng Zhang (8 shared papers)Hui‐Chuan Sun (11 shared papers)
- Journals
- Journal of Clinical Oncology (10 papers)Annals of Surgical Oncology (3 papers)Journal of Biological Chemistry (3 papers)Molecular Cancer Therapeutics (2 papers)Tumor Biology (2 papers)
- Partner nations
- ChinaUnited StatesIndia
In The Last Decade
Ningling Ge
42 papers receiving 1.4k citations
Hit Papers
Peers
Comparison fields: 5 of 80
- Hepatology 708
- Cancer Research 411
- Oncology 505
- Immunology 220
- Epidemiology 328
Countries citing papers authored by Ningling Ge
This map shows the geographic impact of Ningling Ge's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ningling Ge with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ningling Ge more than expected).
Fields of papers citing papers by Ningling Ge
This network shows the impact of papers produced by Ningling Ge. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ningling Ge. The network helps show where Ningling Ge may publish in the future.
Co-authors
The 25 scholars most cited alongside Ningling Ge, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 44 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2018 | 204 | |
| 2 | Downstaging and Resection of Initially Unresectable Hepatocellular Carcinoma with Tyrosine Kinase Inhibitor and Anti-PD-1 Antibody Combinations Hit paper breakdown → | 2021 | 159 |
| 3 | 2009 | 150 | |
| 4 | 2014 | 102 | |
| 5 | 2008 | 96 | |
| 6 | 2009 | 79 | |
| 7 | 2014 | 67 | |
| 8 | 2021 | 48 | |
| 9 | 2015 | 44 | |
| 10 | 2022 | 44 | |
| 11 | 2015 | 44 | |
| 12 | 2012 | 43 | |
| 13 | 2015 | 40 | |
| 14 | 2016 | 27 | |
| 15 | 2014 | 26 | |
| 16 | 2009 | 23 | |
| 17 | 2021 | 23 | |
| 18 | 2021 | 22 | |
| 19 | 2015 | 21 | |
| 20 | 2003 | 19 |
About Ningling Ge
Ningling Ge is a scholar working on Hepatology, Oncology, Cancer Research, Pulmonary and Respiratory Medicine and Immunology, having authored 44 papers that have together received 1.4k indexed citations. Recurring topics across this work include Hepatocellular Carcinoma Treatment and Prognosis (24 papers), Cancer Immunotherapy and Biomarkers (9 papers), Liver Disease Diagnosis and Treatment (7 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (7 papers), Cancer Mechanisms and Therapy (6 papers), Cancer, Lipids, and Metabolism (4 papers), Inflammatory Biomarkers in Disease Prognosis (4 papers) and Pancreatic and Hepatic Oncology Research (4 papers). The work is most often cited by research in Hepatology (708 citations), Cancer Research (411 citations), Oncology (505 citations), Immunology (220 citations) and Epidemiology (328 citations). Ningling Ge has collaborated with scholars based in China, United States and India. Frequent co-authors include Zhenggang Ren, Sheng‐Long Ye, Jia Fan, Yanhong Wang, Lan Zhang, Tong‐Chun Xue, Boheng Zhang, Hui‐Chuan Sun, Jianhua Yang and Songbin Fu. Their work appears in journals such as Journal of Clinical Oncology, Annals of Surgical Oncology, Journal of Biological Chemistry, Molecular Cancer Therapeutics and Tumor Biology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.